• 1. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 2. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514
• 3. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 4. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 5. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043

Recent Advances in the Application of 5-Bromo-2-fluoromethoxy-3-nitropyridine (CAS: 1807088-03-4) in Chemical Biology and Pharmaceutical Research

The compound 5-Bromo-2-fluoromethoxy-3-nitropyridine (CAS: 1807088-03-4) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential applications in drug discovery and development. This heterocyclic compound, characterized by the presence of bromo, fluoromethoxy, and nitro functional groups, serves as a versatile building block for the synthesis of more complex molecules with potential biological activities. Recent studies have explored its utility in the development of kinase inhibitors, antimicrobial agents, and radiopharmaceuticals, highlighting its broad applicability in medicinal chemistry.

One of the key areas of research involving 5-Bromo-2-fluoromethoxy-3-nitropyridine is its role in the synthesis of kinase inhibitors. Kinases are critical targets in the treatment of various cancers and inflammatory diseases, and the introduction of fluorine-containing moieties, such as the fluoromethoxy group in this compound, has been shown to enhance the binding affinity and metabolic stability of kinase inhibitors. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of 5-Bromo-2-fluoromethoxy-3-nitropyridine exhibited potent inhibitory activity against several tyrosine kinases, including EGFR and VEGFR, with improved pharmacokinetic profiles compared to their non-fluorinated counterparts.

In addition to its applications in kinase inhibitor development, 5-Bromo-2-fluoromethoxy-3-nitropyridine has also been investigated for its potential antimicrobial properties. The presence of both bromo and nitro groups in the pyridine ring has been associated with enhanced antibacterial and antifungal activities. A recent study in Bioorganic & Medicinal Chemistry Letters reported that novel derivatives of this compound displayed significant activity against drug-resistant strains of Staphylococcus aureus and Candida albicans, suggesting its potential as a scaffold for the development of new antimicrobial agents.

Another promising application of 5-Bromo-2-fluoromethoxy-3-nitropyridine is in the field of radiopharmaceuticals. The bromine atom in the compound can be replaced with radioactive isotopes such as fluorine-18, making it a valuable precursor for positron emission tomography (PET) imaging agents. A 2022 study in the Journal of Labelled Compounds and Radiopharmaceuticals described the successful synthesis of a fluorine-18 labeled analog of this compound, which demonstrated high uptake in tumor tissues in preclinical models, indicating its potential as a diagnostic tool for cancer imaging.

Despite these promising findings, challenges remain in the optimization of 5-Bromo-2-fluoromethoxy-3-nitropyridine derivatives for clinical use. Issues such as solubility, metabolic stability, and off-target effects need to be addressed through further structural modifications and preclinical studies. However, the compound's versatility and the growing body of research supporting its applications suggest that it will continue to be a valuable tool in chemical biology and pharmaceutical research.

In conclusion, 5-Bromo-2-fluoromethoxy-3-nitropyridine (CAS: 1807088-03-4) represents a promising scaffold for the development of novel therapeutic and diagnostic agents. Its unique structural features enable diverse applications in kinase inhibition, antimicrobial therapy, and radiopharmaceuticals, making it a compound of significant interest in the field. Future research should focus on optimizing its derivatives for improved efficacy and safety, paving the way for their translation into clinical applications.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)